Push launch MHRA approves GLP –1 receptor agonist semaglutide to lower hazard of significant heart issues in obese or overweight Grownups Semaglutide is the primary weight reduction drug authorised in the UK as being a preventative therapy for all those with founded cardiovascular diseaseWegovy® slows tummy emptying and may impact medicines that